President, Head of Research and Development · Syndax Pharmaceuticals Inc (SNDX)

Neil Gallagher

FY2024 is the first fiscal year CompBrief holds for Neil Gallagher as a named executive officer of Syndax Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$2,928,067

Salary $546,000Stock awards $1,065,274

3rd of 5 named executive officers at Syndax Pharmaceuticals by FY2024 total.

5 named officers on file for Syndax Pharmaceuticals, FY2024

Neil Gallagher’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 3 equity grants, each cited to its filing
  • SNDX’s disclosed peer group of 22 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Syndax Pharmaceuticals’s whole pay program stands against its peers

  • Syndax Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SNDX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 1, 2025 (DEF 14A).

Free

Get Neil Gallagher’s full pay file as a PDF — free

More than this page: up to 10 years of Neil’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Neil Gallagher compensation by year

Syndax Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as Syndax Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$546,000
Bonus$0
Stock awards$1,065,274
Option awards$1,037,205
Non-equity incentive$269,588
Pension and deferred compensation$0
All other$10,000
Total$2,928,067

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Syndax Pharmaceuticals Inc DEF 14A filed April 1, 2025, accession 0000950170-25-048472, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Syndax Pharmaceuticals Inc filed document, accession 0000950170-25-048472. Every figure is read from that document and cited to the page and table it appears in. Filed April 1, 2025.

Syndax Pharmaceuticals’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Michael MetzgerChief Executive Officer$7,707,176
Steve ClosterChief Commercial Officer$3,557,137
Neil Gallagher · this pagePresident, Head of Research and Development$2,928,067
Keith GoldanChief Financial Officer$2,824,133
Luke AlbrechtGeneral Counsel and Secretary$2,469,748

The full Syndax Pharmaceuticals compensation record

free company brief

This page is one person within Syndax Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Syndax Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Syndax Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Neil Gallagher's compensation dossier · One-time report. No refunds.